Hoechst Pakistan Limited (PSX:HPL)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
3,021.34
-10.11 (-0.33%)
At close: Aug 1, 2025
-0.33%
Market Cap29.14B
Revenue (ttm)28.03B
Net Income (ttm)2.07B
Shares Out9.64M
EPS (ttm)215.09
PE Ratio14.05
Forward PEn/a
Dividend135.00 (4.45%)
Ex-Dividend DateMar 26, 2025
Volume331
Average Volume956
Open3,050.01
Previous Close3,031.45
Day's Range3,020.01 - 3,050.01
52-Week Range1,440.00 - 3,699.99
Beta0.23
RSI34.98
Earnings DateAug 22, 2025

About HashiCorp

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 837
Stock Exchange Pakistan Stock Exchange
Ticker Symbol HPL
Full Company Profile

Financial Performance

In 2024, Hoechst Pakistan's revenue was 26.75 billion, an increase of 25.17% compared to the previous year's 21.37 billion. Earnings were 1.86 billion, an increase of 414.72%.

Financial Statements

News

There is no news available yet.